Publicaciones en colaboración con investigadores/as de University of Oslo (32)

2024

  1. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

  2. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  3. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

    Haematologica, Vol. 109, Núm. 7, pp. 2239-2249

2023

  1. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  2. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70

  3. Comparison between the difficulty of laparoscopic limited liver resections of tumors located in segment 7 versus segment 8: An international multicenter propensity-score matched study

    Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 30, Núm. 2, pp. 177-191

  4. Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results

    EJHAEM, Vol. 4, Núm. 4, pp. 1117-1131

  5. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

    Leukemia, Vol. 37, Núm. 6, pp. 1175-1185

  6. Neurobiology of eating behavior, nutrition, and health

    Journal of Internal Medicine, Vol. 294, Núm. 5, pp. 582-604

  7. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269

  8. Robotic versus laparoscopic liver resection for huge (≥10 cm) liver tumors: an international multicenter propensity-score matched cohort study of 799 cases

    HEPATOBILIARY SURGERY AND NUTRITION, Vol. 12, Núm. 2, pp. 205-216

  9. Robotic versus laparoscopic liver resection for huge (≥10 cm) liver tumors: an international multicenter propensity-score matched cohort study of 799 cases

    HEPATOBILIARY SURGERY AND NUTRITION, Vol. 12, Núm. 2, pp. 205-216

2022

  1. Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))

    Annals of Oncology

  2. Nutrition and stem cell integrity in aging

    Journal of Internal Medicine, Vol. 292, Núm. 4, pp. 587-603

2021

  1. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946

  2. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

    The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

    HemaSphere, Vol. 5, Núm. 2

  5. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    Annals of Oncology, Vol. 32, Núm. 3, pp. 309-322

  6. The ESSO core curriculum committee update on surgical oncology

    European Journal of Surgical Oncology, Vol. 47, Núm. 11, pp. e1-e30